Torrent Pharma had hit a new 52-week high on the back of its very good numbers for Q4 and Fy14. For Q4FY14, it reported a 41% (YoY) rise in consolidated revenue at Rs.1225 crore. EBITDA rose 59% at Rs.350 crore and EBITDA margins improved from 25% to 29%. It ended the quarter with a net profit of Rs.244 crore, up by a whopping 120%, with NPM also rising from 13% to 20%. For FY14, the company showed a 30% rise in revenue at Rs.4184 crore and net profit was up 53% at Rs.664 crore. EPS for the fiscal was at Rs.39.

During the quarter, domestic formulation business recorded revenues of Rs. 256 crores, growing by 17%. International revenues grew by 69%. Revenues from US operations recorded growth of 335%. Adjusting for currency movements, US operations registered revenue growth of 282% during the quarter. Operations from Brazil showed a de growth of 4%, Europe grew 19% while RoW, including Russia & CIS operations grew 16%. During the year company acquired Indian Branded Formulations business of Elder for a consideration of Rs. 2004 cores. The transaction is expected to close in the first half of 2014.